US$ 26.82
30 mg tirzepatide powder 30mg UPB Tirz 30MG (Double Agonist)
Description
The discontinuation rate due to adverse events sits at just 6% for Tirzepatide

Tirzepatide# Tirzepatide is a 39-amino acid single molecule that simultaneously activates GIP and GLP-1 receptors with approximately 5-fold potency at GIPR relative to native GIP and 0.2-fold at GLP-1R relative to native GLP-1

On March 8, 2024, the FDA (U.S

References 1.Sjstrm L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S

The Pulmonary Embolism Severity Index (PESI) score is a validated tool to help risk stratify patients with PE

Our findings do not support an increased risk of SIS associated with GLP-1RA
